SR-1375 is under clinical development by Shanghai SIMR Biotech and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Covid-19 CD40 RBDv is under clinical development by LinKinVax Europe Spas and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL).

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

PrimePro is under clinical development by Thomas Advanced Medical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

GIP/GLP-1 Coagonist III is under clinical development by Eli Lilly and Co and currently in Phase I for Cardiometabolic Disease.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

QTX-3046 is under development for the treatment of solid tumor, colorectal, pancreatic, endometrial cancer and lung cancer. It is administered through oral route. The drug candidate acts by targeting ...

R3R-01 is under development for the treatment of Alport syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. It is administered through oral route.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.

IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer.